Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVATAR: Bevacizumab and Erlotinib in HLRCC and Sporadic Papillary RCC
NCT01130519Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2010
- Primary completion
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in hereditary leiomyomatosis and renal cell cancer (HLRCC), papillary renal cell carcinoma (PRCC), sponsored by National Cancer Institute. Started May 2010; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
hereditary leiomyomatosis and renal cell cancer (HLRCC)papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT01130519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01130519.